[{"id":"342c2212-312d-4751-97cb-897cdaabd015","acronym":"","url":"https://clinicaltrials.gov/study/NCT06817525","created_at":"2025-02-25T15:38:27.775Z","updated_at":"2025-02-25T15:38:27.775Z","phase":"Phase 2","brief_title":"Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC","source_id_and_acronym":"NCT06817525","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 11/06/2025","primary_completion_date":" 11/06/2025","study_txt":" Completion: 11/06/2025","study_completion_date":" 11/06/2025","last_update_posted":"2025-02-10"},{"id":"fc853ccb-9f4e-4599-bd19-d2d6e2520e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06044025","created_at":"2023-11-29T19:16:19.395Z","updated_at":"2025-02-25T16:40:12.563Z","phase":"Phase 1","brief_title":"A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy","source_id_and_acronym":"NCT06044025","lead_sponsor":"University of Arkansas","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-06"},{"id":"b5925ff8-a414-4e5c-8129-fb6140d88f40","acronym":"PNOC028","url":"https://clinicaltrials.gov/study/NCT05887882","created_at":"2024-06-08T04:17:18.068Z","updated_at":"2025-02-25T17:38:54.746Z","phase":"Phase 1","brief_title":"Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors","source_id_and_acronym":"NCT05887882 - PNOC028","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-01-29"},{"id":"08da958b-deab-46fd-9448-9e7d0dc1d817","acronym":"KEYNOTE B84","url":"https://clinicaltrials.gov/study/NCT04815720","created_at":"2021-03-25T11:52:15.829Z","updated_at":"2025-02-25T16:11:18.429Z","phase":"Phase 1/2","brief_title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04815720 - KEYNOTE B84","lead_sponsor":"Vaccinex Inc.","biomarkers":" PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1","pipe":"","alterations":" ","tags":["PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-01-08"},{"id":"688f7919-86e0-4ff0-8b2a-5d36de39804f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06487624","created_at":"2025-02-26T10:01:41.524Z","updated_at":"2025-02-26T10:01:41.524Z","phase":"Phase 1","brief_title":"An Engineered Sirpα Fused to Anti-Pd-L1 and Tgf-β Fusion Protein (HCB301) in Subjects with Selected Advanced Tumors","source_id_and_acronym":"NCT06487624","lead_sponsor":"FBD Biologics Limited","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-11"},{"id":"7c91b7c5-c822-4ffa-8827-8ecd7763a046","acronym":"","url":"https://clinicaltrials.gov/study/NCT06598007","created_at":"2025-02-26T14:53:31.865Z","updated_at":"2025-02-26T14:53:31.865Z","phase":"Phase 1/2","brief_title":"A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors","source_id_and_acronym":"NCT06598007","lead_sponsor":"Crossignal Therapeutics, Inc.","biomarkers":" IFNG • TNFA • TGFB1","pipe":"","alterations":" ","tags":["IFNG • TNFA • TGFB1"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/20/2024","start_date":" 09/20/2024","primary_txt":" Primary completion: 06/20/2027","primary_completion_date":" 06/20/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-11-04"},{"id":"df5d7551-5615-45b3-a605-842f63e2f72b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02917421","created_at":"2023-12-05T22:52:45.479Z","updated_at":"2024-07-02T16:34:37.642Z","phase":"Phase 1/2","brief_title":"Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations","source_id_and_acronym":"NCT02917421","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 12/19/2016","start_date":" 12/19/2016","primary_txt":" Primary completion: 05/19/2023","primary_completion_date":" 05/19/2023","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-06"},{"id":"da3993b4-3224-43f3-abf3-1a2b44201eaf","acronym":"TINKS","url":"https://clinicaltrials.gov/study/NCT05634369","created_at":"2023-12-20T08:17:53.968Z","updated_at":"2024-07-02T16:34:37.915Z","phase":"Phase 1/2","brief_title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","source_id_and_acronym":"NCT05634369 - TINKS","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • dexamethasone • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-05"},{"id":"e2962ecf-0b50-49e6-96a6-e28d8eca2ad1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05877859","created_at":"2023-05-26T15:07:09.164Z","updated_at":"2024-07-02T16:34:59.728Z","phase":"","brief_title":"Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab","source_id_and_acronym":"NCT05877859","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 04/10/2025","primary_completion_date":" 04/10/2025","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-05-31"},{"id":"4c05af61-5d05-4c37-bd6c-572d69e5c509","acronym":"BETA-PRIME","url":"https://clinicaltrials.gov/study/NCT04673942","created_at":"2024-02-16T15:19:06.027Z","updated_at":"2024-07-02T16:35:04.617Z","phase":"Phase 2","brief_title":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","source_id_and_acronym":"NCT04673942 - BETA-PRIME","lead_sponsor":"EpicentRx, Inc.","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AIM-001"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-05-09"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"da2b0979-fceb-4b41-a878-bc533fb0df47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807126","created_at":"2023-04-11T14:03:25.975Z","updated_at":"2024-07-02T16:35:06.439Z","phase":"Phase 1","brief_title":"Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations","source_id_and_acronym":"NCT05807126","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3","pipe":" | ","alterations":" HR positive • BRCA mutation • CD47 expression","tags":["IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRCA mutation • CD47 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • magrolimab (ONO-7913)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 12/06/2026","primary_completion_date":" 12/06/2026","study_txt":" Completion: 12/06/2026","study_completion_date":" 12/06/2026","last_update_posted":"2024-05-02"},{"id":"f99a8696-8fa3-4a88-8fbc-fa52c7ef12b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03089203","created_at":"2024-04-26T15:50:57.697Z","updated_at":"2024-07-02T16:35:07.388Z","phase":"Phase 1","brief_title":"CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03089203","lead_sponsor":"University of Pennsylvania","biomarkers":" TGFB1","pipe":" | ","alterations":" FOLH1 expression","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/08/2017","start_date":" 03/08/2017","primary_txt":" Primary completion: 09/08/2038","primary_completion_date":" 09/08/2038","study_txt":" Completion: 12/08/2038","study_completion_date":" 12/08/2038","last_update_posted":"2024-04-26"},{"id":"bc0581ed-ffe4-4300-a9b1-846278b1e4af","acronym":"","url":"https://clinicaltrials.gov/study/NCT02797600","created_at":"2021-06-09T12:57:03.838Z","updated_at":"2024-07-02T16:35:11.997Z","phase":"","brief_title":"Community Awareness, Resources and Education (CARE II) Project: Project 1","source_id_and_acronym":"NCT02797600","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Completed","enrollment":" Enrollment 285","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2024-04-02"},{"id":"3a511d5d-3245-4fbd-a2c8-a89db4e723ed","acronym":"CIFRA","url":"https://clinicaltrials.gov/study/NCT03874026","created_at":"2021-01-18T19:06:05.689Z","updated_at":"2024-07-02T16:35:12.803Z","phase":"Phase 2","brief_title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","source_id_and_acronym":"NCT03874026 - CIFRA","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression","tags":["KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 05/19/2023","primary_completion_date":" 05/19/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-26"},{"id":"ebed6945-173e-4776-a370-38c4e9c506b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06322745","created_at":"2024-03-22T06:23:33.618Z","updated_at":"2024-07-02T16:35:13.562Z","phase":"","brief_title":"Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy","source_id_and_acronym":"NCT06322745","lead_sponsor":"Al-Azhar University","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-21"},{"id":"b3ac8ecc-cacf-468c-8c73-aa0d520167f2","acronym":"POISE","url":"https://clinicaltrials.gov/study/NCT02845479","created_at":"2024-03-15T21:34:43.413Z","updated_at":"2024-07-02T16:35:14.527Z","phase":"Phase 3","brief_title":"The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I","source_id_and_acronym":"NCT02845479 - POISE","lead_sponsor":"The Canadian College of Naturopathic Medicine","biomarkers":" IFNG • TNFA • IL2 • IL10 • TGFB1 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL2 • IL10 • TGFB1 • IFNA1"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 12/07/2018","start_date":" 12/07/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/07/2020","study_completion_date":" 12/07/2020","last_update_posted":"2024-03-15"},{"id":"06ab7f9b-1285-4ff7-8e07-6a4608ecb3c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922035","created_at":"2024-02-22T20:26:04.668Z","updated_at":"2024-07-02T16:35:18.238Z","phase":"Phase 1","brief_title":"CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant","source_id_and_acronym":"NCT03922035","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFA • TNFRSF1A • TGFB1","pipe":"","alterations":" ","tags":["TNFA • TNFRSF1A • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cdactin-O (CBM588)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 12/24/2024","study_completion_date":" 12/24/2024","last_update_posted":"2024-02-22"},{"id":"189af0e0-df53-44e2-bea1-ee75b0bbd519","acronym":"KIWIS","url":"https://clinicaltrials.gov/study/NCT03996096","created_at":"2021-01-18T19:38:46.410Z","updated_at":"2024-07-02T16:35:19.368Z","phase":"","brief_title":"Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.","source_id_and_acronym":"NCT03996096 - KIWIS","lead_sponsor":"University Hospital, Caen","biomarkers":" VEGFA • IFNG • IL6 • TNFA • IL2 • IL10 • TGFB1 • TNFRSF11B","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • TNFA • IL2 • IL10 • TGFB1 • TNFRSF11B"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/23/2019","start_date":" 04/23/2019","primary_txt":" Primary completion: 03/16/2023","primary_completion_date":" 03/16/2023","study_txt":" Completion: 03/16/2023","study_completion_date":" 03/16/2023","last_update_posted":"2024-02-14"},{"id":"a442140a-cf73-49ad-8943-04880441287b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06223308","created_at":"2024-01-25T16:19:06.568Z","updated_at":"2024-07-02T16:35:22.215Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT06223308","lead_sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","biomarkers":" PD-L1 • TGFB1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2022","start_date":" 09/09/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-01-25"},{"id":"34044c3f-866c-4f4c-90fc-aa39c3bd8a17","acronym":"","url":"https://clinicaltrials.gov/study/NCT05976555","created_at":"2024-01-16T18:18:52.892Z","updated_at":"2024-07-02T16:35:23.383Z","phase":"Phase 1","brief_title":"Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma","source_id_and_acronym":"NCT05976555","lead_sponsor":"Medical College of Wisconsin","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-01-15"},{"id":"e1789d3b-7f73-4e03-8844-1658c55f879a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01704274","created_at":"2021-01-18T07:25:02.274Z","updated_at":"2024-07-02T16:35:23.730Z","phase":"Phase 2","brief_title":"GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy","source_id_and_acronym":"NCT01704274","lead_sponsor":"Dr. D. Robert Siemens","biomarkers":" PD-L1 • TGFB1 • ULBP2","pipe":"","alterations":" ","tags":["PD-L1 • TGFB1 • ULBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nitroglycerin"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2024-01-11"},{"id":"97d926d0-be37-423b-83a2-cb239072fda6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464810","created_at":"2022-07-19T14:54:34.432Z","updated_at":"2024-07-02T16:35:27.090Z","phase":"Phase 1","brief_title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05464810","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2023-12-05"},{"id":"d0276491-b6d2-431d-8702-c6ec3512d495","acronym":"","url":"https://clinicaltrials.gov/study/NCT05637216","created_at":"2023-10-16T17:13:10.642Z","updated_at":"2024-07-02T16:35:33.465Z","phase":"Phase 2","brief_title":"Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients","source_id_and_acronym":"NCT05637216","lead_sponsor":"Shaw Cancer Center","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/17/2023","start_date":" 08/17/2023","primary_txt":" Primary completion: 08/17/2027","primary_completion_date":" 08/17/2027","study_txt":" Completion: 08/17/2027","study_completion_date":" 08/17/2027","last_update_posted":"2023-10-16"}]